Role of argatroban infusion in controlling clot formation in post-cardiac surgical extracorporeal membrane oxygenation in pediatrics: A case series of three patients
Research article published in Perfusion (2026)
Abstract
Anticoagulation in pediatric patients on extracorporeal membrane oxygenation (ECMO) presents significant challenges. Direct thrombin inhibitors (DTIs), such as argatroban, are increasingly considered when heparin is ineffective or contraindicated. However, guidelines regarding optimal dosing and monitoring remain established. This case series examines three pediatric patients who received argatroban infusion following cardiac surgery. We focus on titration challenges, complications, and outcomes. Patient 1, a 3-month-old girl, required a gradual increase in argatroban to 0.7 mcg/kg/min over 8 days. Patient 2, a 3-year-old boy, transitioned to argatroban due to suspected heparin-induced thrombocytopenia (HIT) and required doses up to 1.43 mcg/kg/min. Patient 3, a 23-month-old boy, reached 2.13 mcg/kg/min over 39 days. While patients were successfully decannulated, complications included arterial thrombosis, circuit thrombosis, and mild intracranial hemorrhage. In our series, effective argatroban doses ranged widely (0.18 to 2.13 mcg/kg/min), highlighting the need for individualized dosing, while optimal monitoring strategies remain to be established; lower doses are recommended for patients with hepatic impairment.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Anticoagulation in pediatric patients on extracorporeal membrane oxygenation (ECMO) presents significant challenges.
Por qué esto importa para la hirudoterapia
Esta serie de casos examina los desafíos de titulación, las complicaciones y los desenlaces clínicos de la infusión de argatrobán para el manejo de la anticoagulación en tres pacientes pediátricos en oxigenación por membrana extracorpórea tras cirugía cardiaca, destacando el amplio rango de dosis efectivas y la necesidad de dosificación individualizada. El resumen identifica al argatrobán como un inhibidor directo de la trombina, pero no menciona sanguijuelas, hirudina, hirudoterapia ni el secretoma de la sanguijuela. Como serie de casos pequeña centrada en un anticoagulante farmacéutico en ECMO pediátrica, su relevancia para la American Society of Hirudotherapy es negligible, sin conexión alguna con las terapias basadas en sanguijuelas.
Citación
Role of argatroban infusion in controlling clot formation in post-cardiac surgical extracorporeal membrane oxygenation in pediatrics: A case series of three patients
Samhan LM et al. · Perfusion, 2026
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026